Document:

Second Amendment, dated December 29, 2008, to Pediatrix Medical Group, Inc. 2004

 Exhibit 10.8 
 Execution Copy 
 SECOND AMENDMENT TO THE 
 PEDIATRIX MEDICAL GROUP, INC. 
 2004
INCENTIVE COMPENSATION PLAN 
 THIS AMENDMENT (the “Amendment”), made on this 29th day of December, 2008, to the
PEDIATRIX MEDICAL GROUP, INC. 2004 INCENTIVE COMPENSATION PLAN, by Mednax, Inc., a Florida Corporation (the “Company”). 
 W I T N E S S E T H: 
 WHEREAS, Pediatrix
Medical Group, Inc., a Florida corporation (“PMG”), did establish the 2004 Incentive Compensation Plan effective as of May 20, 2004, which plan was amended effective as of September 24, 2008 (the “2004 Plan”); and

 WHEREAS, pursuant to an Agreement and Plan of Merger dated December 29, 2008, between the Company, PMG and PMG Merger
Sub, Inc., a Florida corporation (the “Merger Agreement”), PMG assigned to the Company all of its outstanding obligations pursuant to (i) PMG’s stock option plans, incentive compensation plans, employee stock purchase plans and
other benefit plans pursuant to which PMG’s common stock is issuable, effective as of the “Effective Time” as set forth in the Merger Agreement (the “Effective Time”); 
 WHEREAS, the Company now wishes to amend the 2004 Plan as of the Effective Time to reflect that assignment so as to (i) designate the Company
as the “Company” wherever that term is used in the Plan, (ii) change the name of the Plan to reflect the name of the Company, and (iii) make additional modifications on account of the fact that the Company is the new plan sponsor
and the issuer of Shares thereunder. 
 NOW, THEREFORE, as of the Effective Time, the 2004 Plan shall be and hereby is amended as
follows: 
 1. The name of the Plan is hereby changed to the “Mednax, Inc. 2004 Incentive Compensation Plan”, and all references to
“Company” in the Plan shall hereinafter refer to Mednax, Inc., a Florida corporation. 
 2. Section 1 of the 2004 Plan hereby
is amended in its entirety to read as follows: 
 “1. The purpose of this 2004 INCENTIVE COMPENSATION PLAN (the
“Plan”) is to assist Mednax, Inc., a Florida corporation (the “Company”) and its Related Entities (as hereinafter defined) in attracting, motivating, retaining and rewarding high-quality executives and other employees, officers,
directors, consultants and other persons who provide services to the Company or its Related Entities by enabling such persons to acquire or increase a proprietary interest in the Company in order to strengthen the mutuality of interests between such
persons and the Company’s shareholders, and 

 
providing such persons with annual and long term performance incentives to expend their maximum efforts in the creation of shareholder value. The Plan is
intended to qualify certain compensation awarded under the Plan for tax deductibility under Section 162(m) of the Code (as hereafter defined) to the extent deemed appropriate by the Committee (as defined below). 
 Pursuant to the terms of an Agreement and Plan of Merger dated December 29, 2008 (the “Merger Agreement”, between Pediatrix
Medical Group, Inc., a Florida corporation (“Pediatrix”), the Company and PMG Merger Sub, Inc. (“Merger Sub”), Merger Sub was merged into Pediatrix effective as of 11:59 P.M. on December 31, 2008 (the “Effective
Time”) and as a result Pediatrix became a wholly owned subsidiary of the Company. Also pursuant to the terms of the Merger Agreement, at the Effective Time: (i) each share of common stock of Pediatrix, together with attached preferred
share purchase right (“Pediatrix Common Stock”), was converted into one share of common stock of the Company, together with attached preferred share purchase right (“Company Common Stock”); (ii) each share of restricted
Pediatrix Common Stock that was restricted under the Plan, whether or not then vested or exercisable, was converted into a restricted share of Company Common Stock, restricted on substantially the same terms and conditions (including without
limitation, vesting schedule) as a applied to such share of restricted share of Pediatrix Common Stock immediately prior to the Effective Time; and (iii) each option to purchase shares of Pediatrix Common Stock issued under the Plan, that was
outstanding immediately prior to the Effective Time, whether or not then vested or exercisable, was converted into an option to purchase the same number of shares of the Company Common Stock, on substantially the same terms and conditions
(including, without limitation, vesting schedule and per share exercise price) as applied to such option to purchase Pediatrix Common Stock.” 
 3. In all other respects, the 2004 Plan shall remain unchanged by the Amendment. 
 IN WITNESS WHEREOF, the Company
has caused this instrument to be executed the day and year first written above. 
  

			
	MEDNAX, INC.
		
	By:	 	/s/ Karl B. Wagner
	Name:	 	Karl B. Wagner
	Title:	 	President

  

 2First Amendment, dated December 29, 2008, to Pediatrix Medical Group, Inc. 2008

 Exhibit 10.9 
 Execution Copy 
 FIRST AMENDMENT TO THE 
 PEDIATRIX MEDICAL GROUP, INC. 
 2008
INCENTIVE COMPENSATION PLAN 
 THIS FIRST AMENDMENT (the “Amendment”), made on this 29th day of December, 2008, to the
PEDIATRIX MEDICAL GROUP, INC. 2008 INCENTIVE COMPENSATION PLAN, by Mednax, Inc., a Florida Corporation (the “Company”). 
 W I T N E S S E T H: 
 WHEREAS, Pediatrix
Medical Group, Inc., a Florida corporation (“PMG”), did establish the 2008 Incentive Compensation Plan effective as of May 23, 2008 (the “2008 Plan”); and 
 WHEREAS, pursuant to an Agreement and Plan of Merger dated December 29, 2008, between the Company, PMG and PMG Merger Sub, Inc., a
Florida corporation (the “Merger Agreement”), PMG assigned to the Company all of its outstanding obligations pursuant to (i) PMG’s stock option plans, incentive compensation plans, employee stock purchase plans and other benefit
plans pursuant to which PMG’s common stock is issuable, effective as of the “Effective Time” as set forth in the Merger Agreement (the “Effective Time”); 
 WHEREAS, the Company now wishes to amend the 2008 Plan as of the Effective Time to reflect that assignment so as to (i) designate the Company
as the “Company” wherever that term is used in the Plan, (ii) change the name of the Plan to reflect the name of the Company, and (iii) make additional modifications on account of the fact that the Company is the new plan sponsor
and the issuer of Shares thereunder. 
 NOW, THEREFORE, as of the Effective Time, the 2008 Plan shall be and hereby is amended as
follows: 
 1. The name of the Plan is hereby changed to the “Mednax, Inc. 2008 Incentive Compensation Plan”, and all references to
“Company” in the Plan shall hereinafter refer to Mednax, Inc., a Florida corporation. 
 2. Section 1 of the 2008 Plan hereby
is amended in its entirety to read as follows: 
 “1. The purpose of this 2008 INCENTIVE COMPENSATION PLAN (the
“Plan”) is to assist Mednax, Inc., a Florida corporation (the “Company”) and its Related Entities (as hereinafter defined) in attracting, motivating, retaining and rewarding high-quality executives and other employees, officers,
directors, consultants and other persons who provide services to the Company or its Related Entities by enabling such persons to acquire or increase a proprietary interest in the Company in order to strengthen the mutuality of interests between such
persons and the Company’s shareholders, and providing such persons with annual and long term performance incentives to expend their maximum efforts in the creation of shareholder value. 

 Pursuant to the terms of an Agreement and Plan of Merger dated December 29, 2008
(the “Merger Agreement”, between Pediatrix Medical Group, Inc., a Florida corporation (“Pediatrix”), the Company and PMG Merger Sub, Inc. (“Merger Sub”), Merger Sub was merged into Pediatrix effective as of 11:59 P.M.
on December 31, 2008 (the “Effective Time”) and as a result Pediatrix became a wholly owned subsidiary of the Company. Also pursuant to the terms of the Merger Agreement, at the Effective Time: (i) each share of common stock of
Pediatrix, together with attached preferred share purchase right (“Pediatrix Common Stock”), was converted into one share of common stock of the Company, together with attached preferred share purchase right (“Company Common
Stock”); (ii) each share of restricted Pediatrix Common Stock that was restricted under the Plan, whether or not then vested or exercisable, was converted into a restricted share of Company Common Stock, restricted on substantially the
same terms and conditions (including without limitation, vesting schedule) as a applied to such share of restricted share of Pediatrix Common Stock immediately prior to the Effective Time; and (iii) each option to purchase shares of Pediatrix
Common Stock issued under the Plan, that was outstanding immediately prior to the Effective Time, whether or not then vested or exercisable, was converted into an option to purchase the same number of shares of the Company Common Stock, on
substantially the same terms and conditions (including, without limitation, vesting schedule and per share exercise price) as applied to such option to purchase Pediatrix Common Stock.” 
 3. The definition contained in Section 2(ii) of the 2008 Plan hereby is amended in its entirety to read as follows: 
 “(ii) “Prior Plan” means the Mednax, Inc. 2004 Incentive Compensation Plan (f/k/a Pediatrix Medical Group,
Inc. 2004 Incentive Compensation Plan).” 
 4. In all other respects, the 2008 Plan shall remain unchanged by the Amendment. 

IN WITNESS WHEREOF, the Company has caused this instrument to be executed the day and year first written above. 
  

			
	MEDNAX, INC.
		
	By:	 	/s/ Karl B. Wagner
	Name:	 	Karl B. Wagner
	Title:	 	President

  

 2Amendment No. 2 to Amended and Restated Credit Agreement

 Exhibit 4.1 
 AMENDMENT NO. 2 TO AMENDED AND RESTATED 
 CREDIT AGREEMENT 
 THIS AMENDMENT NO. 2 TO AMENDED AND RESTATED CREDIT AGREEMENT (this “Amendment”), is entered into as of December 30, 2008 by
and among the lenders identified on the signature pages hereof (such lenders, together with their respective successors and permitted assigns, are referred to hereinafter each individually as a “Lender” and collectively as the
“Lenders”), WELLS FARGO FOOTHILL, INC., a California corporation, as the arranger and administrative agent for the Lenders (in such capacity, together with its successors and permitted assigns in such capacity,
“Agent”), HUDSON HIGHLAND GROUP, INC., a Delaware corporation (“Parent”), and each of Parent’s Subsidiaries identified on the signature pages of the Credit Agreement (such Subsidiaries, together with
Parent, are referred to hereinafter each individually as a “Borrower”, and individually and collectively, jointly and severally, as the “Borrowers”). 
 W I T N E S S E T H 
 WHEREAS, Lenders, Agent and Borrowers are parties to that certain Amended and Restated Credit Agreement, dated as of July 31, 2007 (as amended, restated, supplemented, extended, renewed or otherwise modified from
time to time, the “Credit Agreement”); and 
 WHEREAS, Borrowers have requested that the Credit Agreement be amended to
modify certain terms thereof, as more fully set forth herein; and 
 WHEREAS, subject to the satisfaction of the conditions set forth herein,
Agent and Lenders are willing to agree to amend the Credit Agreement upon the terms and conditions set forth herein. 
 NOW, THEREFORE, for
good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties agree as follows: 
 1. DEFINITIONS.
Capitalized terms used herein and not otherwise defined herein shall have the meanings ascribed to them, respectively, in the Credit Agreement, as amended hereby. 
 2. AMENDMENTS. 
 (a) Section 2.6(b) of the Credit Agreement is hereby amended and restated in its entirety as
follows: 
 “(b) Letter of Credit Fee. Borrowers shall pay Agent (for the ratable benefit of the Lenders, subject
to any agreements between Agent and individual Lenders), a Letter of Credit fee (in addition to the charges, commissions, fees, and costs set forth in Section 2.12(e)) which shall accrue at a rate equal to 2.5% per annum times the Daily
Balance of the undrawn amount of all outstanding Letters of Credit.” 
 (b) Section 5.5 of the Credit Agreement is hereby amended
and restated in its entirety as follows: 
 “5.5 Inspection; Field Audits and Examinations. Permit Agent,
each Lender at such Lender’s expense, and each of their duly authorized representatives or agents to visit any of its properties and inspect any of its assets or Books and Records, to examine and make copies of 

 
its Books and Records, and to discuss its affairs, finances, and accounts with, and to be advised as to the same by, its officers and employees at such
reasonable times and intervals as Agent may designate and, so long as no Default or Event of Default exists, with reasonable prior notice to Administrative Borrower and during normal business hours.” 
 (c) Section 6.10 of the Credit Agreement is hereby amended and restated in its entirety as follows: 
 “6.10 Distributions. Other than distributions or declaration and payment of dividends by a Borrower to another
Borrower, by a Guarantor to a Borrower or another Guarantor, or by a Subsidiary to a Borrower, a Guarantor or another Subsidiary, make any distribution or declare or pay any dividends (in cash or other property, other than common Stock) on, or
purchase, acquire, redeem, or retire any of any Borrower’s Stock, of any class, whether now or hereafter outstanding. Notwithstanding the foregoing, Borrowers may purchase, acquire, redeem, or retire Stock in an aggregate amount not more than
(a) $10,000,000 in each fiscal year through and including the fiscal year ending December 31, 2007, and (b) $11,000,000 during the period from January 1, 2008 through and including February 28, 2009; provided, that
immediately prior to and upon giving effect to each such purchase, acquisition, redemption and retirement, no Default or Event of Default has occurred and is continuing.” 
 (d) Section 6.16 of the Credit Agreement is hereby amended and restated in its entirety as follows: 
 “6.16 Financial Covenants. 
 (a) Minimum Availability. Fail to maintain at all times Availability of at least $25,000,000. 
 (b) Capital Expenditures. Make Capital Expenditures in excess of (i) $18,000,000 in the fiscal year ending December 31,
2008, (ii) $9,000,000 in the fiscal year ending December 31, 2009 and (iii) $11,000,000 in each fiscal year thereafter.” 
 (e) The following definitions in Schedule 1.1 to the Credit Agreement are hereby amended and restated in their entirety as follows: 
 ““Base Rate” means, the rate of interest announced, from time to time, within Wells Fargo at its principal office in San Francisco as its “prime rate”, with the understanding that the
“prime rate” is one of Wells Fargo’s base rates (not necessarily the lowest of such rates) and serves as the basis upon which effective rates of interest are calculated for those loans making reference thereto and is evidenced by the
recording thereof after its announcement in such internal publications as Wells Fargo may designate; provided, that, notwithstanding the foregoing, in no event shall the Base Rate at any time be less than 4.25% per annum.” 
 ““Base Rate Margin” means, (a) at any time in which Availability during the immediately preceding period of
thirty (30) days is greater than $50,000,000, 2.00 percentage points, (b) at any time in which Availability during the immediately preceding period of thirty (30) days is equal to or less than $50,000,000, but greater than
$30,000,000, 2.25 percentage points, and (c) at any time in which Availability during the immediately preceding period of thirty (30) days is equal to or less than $30,000,000, 2.50 percentage points; provided, that each increase and each
decrease in the Base Rate Margin shall be effective on and as of the first day of the calendar month immediately following the date on which Availability falls below or increases above the applicable threshold.” 
  

 2 

 ““LIBOR Rate” means, for each Interest Period for each LIBOR Rate Loan,
the rate per annum determined by Agent by dividing (a) the Base LIBOR Rate for such Interest Period, by (b) 100% minus the Reserve Percentage; provided, that, notwithstanding the foregoing, in no event shall the LIBOR Rate at any time be
less than 2.50% per annum. The LIBOR Rate shall be adjusted on and as of the effective day of any change in the Reserve Percentage.” 
 ““LIBOR Rate Margin” means, (a) at any time in which Availability during the immediately preceding period of thirty (30) days is greater than $50,000,000, 3.50 percentage points, (b) at
any time in which Availability during the immediately preceding period of thirty (30) days is equal to or less than $50,000,000, but greater than $30,000,000, 3.75 percentage points, and (c) at any time in which Availability during the
immediately preceding period of thirty (30) days is equal to or less than $30,000,000, 4.00 percentage points; provided, that each increase and each decrease in the LIBOR Rate Margin shall be effective on and as of the first day of the calendar
month immediately following the date on which Availability falls below or increases above the applicable threshold.” 
 (f) Clauses
(c) and (d) in the definition of the term “Permitted Cash Acquisition” in Schedule 1.1 to the Credit Agreement are hereby amended and restated in their entirety as follows: 
 “(c) Borrowers and their Subsidiaries shall have Availability plus Qualified Cash in an amount equal to $25,000,000 immediately after
giving effect to the consummation of the proposed Acquisition; 
 (d) the purchase consideration payable in respect of all
Permitted Cash Acquisitions, in the aggregate in each fiscal year (including the proposed Acquisition and including deferred payment obligations) shall not exceed $10,000,000 in the aggregate in each fiscal year;” 
 3. AMENDMENT FEE. In consideration of the amendments herein, on the date hereof, Borrowers shall pay to Agent, for the ratable benefit of Lenders, an
amendment fee in the amount of $150,000 (the “Amendment Fee”). The Amendment Fee shall be fully earned on the date hereof, shall not be subject to refund, rebate or proration for any reason whatsoever, and shall be charged by Agent
to the Loan Account as of January 1, 2009. 
 4. CONSTRUCTION. THIS AMENDMENT SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE
LAW OF THE STATE OF NEW YORK APPLICABLE TO CONTRACTS MADE AND TO BE PERFORMED IN THE STATE OF NEW YORK. 
 5. ENTIRE AMENDMENT; EFFECT OF
AMENDMENT. This Amendment, and the terms and provisions hereof, constitute the entire agreement among the parties pertaining to the subject matter hereof and supersede any and all prior or contemporaneous amendments relating to the subject
matter hereof. Except as expressly provided herein, the Credit Agreement and other Loan Documents shall remain unchanged and in full force and effect. To the extent any terms or provisions of this Amendment conflict with those of the Credit
Agreement or other Loan Documents, the terms and provisions of this Amendment shall control. This Amendment is a Loan Document. 
 6. COUNTERPARTS;
DELIVERY. This Amendment may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument and any of the parties hereto may execute this Amendment by signing any such counterpart.
Delivery of an executed 
  

 3 

 counterpart of this Amendment by telefacsimile or other electronic transmission shall be equally as effective as delivery
of an original executed counterpart of this Amendment. Any party delivering an executed counterpart of this Amendment by telefacsimile or other electronic transmission also shall promptly deliver an original executed counterpart of this Amendment,
but the failure to deliver an original executed counterpart shall not affect the validity, enforceability, and binding effect of this Amendment. 
 7.
MISCELLANEOUS. 
 (a) Upon the effectiveness of this Amendment, each reference in the Credit Agreement to “this
Agreement”, “hereunder”, “herein”, “hereof” or words of like import referring to the Credit Agreement shall mean and refer to the Credit Agreement as heretofore amended and as further amended by this Amendment.

 (b) Upon the effectiveness of this Amendment, each reference in the Loan Documents to the “Credit Agreement”,
“thereunder”, “therein”, “thereof” or words of like import referring to the Credit Agreement shall mean and refer to the Credit Agreement as heretofore amended and as further amended by this Amendment. 
 [SIGNATURE PAGE FOLLOWS] 
  

 4 

 IN WITNESS WHEREOF, the parties have caused this Amendment to be executed and delivered as of the date
first written above. 
  

			
	HUDSON HIGHLAND GROUP, INC.,
	as a Borrower and on behalf of the Borrowers and Guarantors
		
	By:	 	 /s/ Elaine A. Kloss

		 	Elaine A. Kloss
		 	Vice President, Finance and Treasurer
	
	WELLS FARGO FOOTHILL, INC.,
	as Agent and as a Lender
		
	By:	 	 /s/ Sean Spring

		 	Sean Spring
		 	Vice President
	
	THE CIT GROUP/BUSINESS CREDIT, INC.
	as a Lender
		
	By:	 	 /s/ Jon Eckhouse

		 	Jon Eckhouse
		 	Vice President

 Amendment No.2

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00151-of-00352.parquet"}]]